Fewer Arrows Left In Quincy's Quiver To Defend Against FTC's Prevagen Supplement Complaint
Executive Summary
"There is no need to litigate the same issue again," says District Judge Louis Stanton in granting most of the joint motions by FTC and New York attorney general to strike Quincy Bioscience's proposed defenses. The judge denied other motions, including whether NY state laws are applicable, saying a trial is needed to weigh the evidence.
You may also be interested in...
Jurors' Answers In FTC's Prevagen Complaint Might Burst A Memory Bubble For Health Claims
“No” answers in New York federal court on whether all but two of Prevagen claims were “materially misleading” could put a fork in the road of a long dispute between FTC and supplement product manufacturers and marketers.
FTC’s Monetary Relief Claims Dismissed In Prevagen Fraud Case; Supreme Court Decision Cited
The Federal Trade Commission’s claim for monetary relief against the Prevagen memory supplement marketer is dismissed by a federal judge in New York, who cites recent Supreme Court decision gutting the agency's long-favored mechanism for collecting monetary penalties under the FTC Act.
‘Clinically Proven’ Claim Leaving RB's Brain Health Supplements In US Class Action Settlement
Settlement in Southern District of Florida federal court includes a consolidated class action complaint against UK firm’s US businesses comprising cases in Florida, New York and California – filed in 2020 over statements the products were “clinically proven” to improve “brain performance” including focus, memory, learning, accuracy, concentration and reasoning.